FindTrial
Sign In

Efficacy and Safety of Bupivacaine Liposomes Combined with Dexamethasone in the Perioperative Period of Total Hip Replacement

Efficacy and Safety of Bupivacaine Liposomes Combined with Dexamethasone in the Perioperative Period of Total Hip Replacement

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600122019
Enrollment
Unknown
Registered
2026-04-08
Start date
2026-04-10
Completion date
Unknown
Last updated
2026-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Arthrosis

Interventions

A:dexamethasone
B:dexamethasone, Bupivacaine liposomes

Sponsors

People's Hospital of Zhuang Autonomous Region
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Patients undergoing the first unilateral total hip arthroplasty; 2. Patients who agree to participate in the trial and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Patients allergic to dexamethasone and liposomal bupivacaine; 2. Patients with alcohol or drug abuse; 3. Patients under the age of 18 or over 75; 4. Patients who have taken glucocorticoids 3 months before the surgery; 5. Patients who have taken strong opioid drugs 1 week before the surgery; 6. Patients with severe heart disease (NYHA > 2) and liver or kidney failure; 7. Patients with concurrent rheumatic diseases (rheumatoid arthritis, ankylosing spondylitis, systemic lupus erythematosus, etc.).

Design outcomes

Primary

MeasureTime frame
PONV;VAS;—

Secondary

MeasureTime frame
Bleeding;IL-6;CRP;SSI;—

Countries

China

Contacts

Public ContactFulin Li

People's Hospital of Zhuang Autonomous Region

qyylifulin@126.com+86 177 5864 8038

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 17, 2026